iSEEK - Web

The majority of ongoing HER2-targeted trials are investigating the efficacy of lapatinib in the neoadjuvant setting for HER2 + breast cancer (Table 1) [16–24].Most of these studies use pCR as a primary endpoint. pCR has been proven to correlate with survival endpoints (DFS and OS) in neoadjuvant chemotherapeutic trials [25, 26] but its precise definition is still debated.

https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2209

Average Rating (0 votes)

Back to search results

Total time to process: 932ms - Cache load: 0ms.

Send Results to a Friend

Do you want to save this as a favorite page?

iSEEK provides users with a Favorites library that allows them easy access to their most-used websites from any computer. If you have an iSEEK account, the content you just selected can be added to your Favorites page to be revisited any time you want.

If you would like to join the iSEEK community, click the "Register" button below to create your free iSEEK account. The resource you have selected will be added to your new Favorites library after you sign in for the first time.

If you already have an iSEEK account, click the button below to sign in and add the resource to your Favorites library.